Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis forms strategic partnership with Lonza

Novartis forms strategic partnership with Lonza

14th July 2008

Novartis has entered into a strategic partnership with Lonza with the goal of accelerating the growth of its product pipeline in biologics.

The company said this collaboration agreement would facilitate the quick scaling up of its development and production efforts in its this area, which currently accounts for a quarter of its research and development portfolio.

It said the combination of the leadership in process development and manufacturing provided by Lonza with its own robust research and development capabilities will result in an ideal long-term collaboration between the companies.

Under the terms of the partnership, each biologics project will be covered by a specific development agreement.

In the case of a successful development of a compound, Novartis will have the option to transfer the commercial manufacturing of the drug in-house.

Mark Levick, global head of biologics at Novartis, said: “The strategic partnership provides a win-win for both companies.

“It gives Novartis access to the most advanced technology and processes available to develop new biological medicines faster for the benefit of patients.”

He added that the deal also facilitates the delay of investments into manufacturing by Novartis.

Last week, Novartis announced the purchase of a 51.7 per cent stake in Speedel, bringing its share in the company up to 61.4 per cent.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.